Results 211 to 220 of about 21,740 (297)
Long‐Term Temporal Profile of Motor Recovery After Intracerebral Hemorrhage
ABSTRACT Objective Limited data is available to describe the temporal profile of long‐term recovery over 1 year after the stroke in patients with spontaneous intracerebral hemorrhage (ICH). Methods A registered multicentral cohort was conducted to consecutively include non‐herniated supratentorial ICH patients from November 2013 to January 2023 ...
Yan Zheng+24 more
wiley +1 more source
In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics
ABSTRACT Objective Natural killer (NK) cells might contribute to motor neuron death in amyotrophic lateral sclerosis (ALS) through direct cytotoxicity, a process that could be inhibited with the FDA‐approved JAK/STAT pathway inhibitor, tofacitinib. This study aimed to verify that tofacitinib can suppress NK cell cytotoxicity, investigate if immune cell
Benjamin J. Murdock+8 more
wiley +1 more source
Neural fields for rapid aircraft aerodynamics simulations. [PDF]
Catalani G+5 more
europepmc +1 more source
Integrated Design of Aerodynamics and Control System for Micro Air Vehicles.
Itsuro KAJIWARA, Raphael T. Haftka
openalex +2 more sources
Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji+9 more
wiley +1 more source
Acoustic, aerodynamic, and vibrational effects of ventricular folds adduction in an ex vivo experiment. [PDF]
Xiao Z, Kang J, Su J, Ge P, Zhang S.
europepmc +1 more source
Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia+20 more
wiley +1 more source
Hydrogen-Induced Ductility Loss of GH625 Superalloy Under Thermal Hydrogen Charging. [PDF]
Zhang J+6 more
europepmc +1 more source